FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington. | DC | 20549 | |
|-------------|----|-------|--|

| STATEMENT | ΩF | CHANGES | IN | BENEFICIAL | OWNERSHIP |
|--------------|----|---------|----|-------------------|---------------|
| CIAICINICIAI | O. | CHANCES | | DEMEN IOIAL | CVVIALITORIII |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response. | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Nuss John | | | 2. Issuer Name and Ticker or Trading Symbol Ventyx Biosciences, Inc. [VTYX] | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director | | | | | | | | |
|--|--|---------------|---|--|--|---|---|---------------------|---|--|--|--|--|--|--------|--------------|-----|
| (Last) | , | irst) | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 01/02/2024 | | | |) Y | X Officer (give title Officer (sp below) Chief Scientific Officer | | | | Decily | | | |
| C/O VE | NTYX BIO | SCIENCES, INC | 2. | | | | | | | | | | | | | | |
| 12790 EI | L CAMINO | REAL, SUITE | 200 | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | Line | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) | | | | | | | | | | | |) | _ | , | | rting Person | |
| SAN DII | EGO C | A | 92130 | | | | | | | | | | Form fil Person | ed by More | e than | One Report | ing |
| (City) | (S | tate) | (Zip) | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | |
| | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | is intended to | satisfy | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transc Date (Month/D | | | action 2A. Deemed Execution Date if any (Month/Day/Year) | | e, Transaction Dispose Code (Instr. | | rities Acquired (A) or d Of (D) (Instr. 3, 4 and | | 5. Amoun Securities Beneficia Owned Fo | Form (D) or ollowing (I) (In | | : Direct II Indirect E str. 4) C | 7. Nature of ndirect Beneficial Dwnership Instr. 4) | | | | |
| | | | | | Code | v | Amount | (A) o (D) | r Price | Transaction (Instr. 3 and | ction(s) | | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | Derivative Conversion Date Execution Date, Tr Security or Exercise (Month/Day/Year) if any C | | Co | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4) | | | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | Cod | de V | (A) | (D) | Date Exercisable | | xpiration ate | Title | Amount or Number of Shares | | Transacti (Instr. 4) | on(s) | | |
| Stock Option (Right to Buy) | \$2.49 | 01/02/2024 | | A | | 125,000 | | (1) | 01 | 1/02/2034 | Common Stock | 125,000 | \$0.00 | 125,00 | 00 | D | |

Explanation of Responses:

1. 100% of the total shares subject to the Option shall vest on the one-year anniversary of January 2, 2024, subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through such date.

Remarks:

/s/ Christopher Krueger, as 01/03/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.